POSB320 Matching-Adjusted Indirect Comparison of Guselkumab Versus Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Change in Baseline PASI from Week 4-40
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.1003
https://www.valueinhealthjournal.com/article/S1098-3015(21)02798-4/fulltext
Title :
POSB320 Matching-Adjusted Indirect Comparison of Guselkumab Versus Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Change in Baseline PASI from Week 4-40
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02798-4&doi=10.1016/j.jval.2021.11.1003
First page :
Section Title :
Open access? :
No
Section Order :
10539